[关键词]
[摘要]
目的 观察依达拉奉联合丁苯酞治疗急性脑梗死的临床疗效。方法 选取200例在宝鸡市人民医院就诊的急性脑梗死患者,随机分为观察组100例,给予依达拉奉注射液联合丁苯酞治疗,对照组100例,仅给予丁苯酞治疗。对两组患者的临床疗效、NDS评分、MoCA评分、ADL评分及血清C-反应蛋白(hs-CRP)水平及不良反应进行比较。结果 观察组总有效率(92%)显著高于对照组(79%),差异具有统计学意义(P<0.05)。治疗后两组患者神经功能缺损均有所下降,认知功能均有所改善,但观察组神经功能缺损下降显著低于对照组,认知功能改善优于对照组,观察组ADL评分显著高于对照组,hs-CRP水平显著低于对照组,差异具有统计学意义(P<0.05)。所有患者治疗过程中无明显不良反应。结论 依达拉奉注射液联合丁苯酞对急性脑梗死疗效显著,安全性好,值得临床推广。
[Key word]
[Abstract]
Objective To observe the clinical effect of edaravone combined with butylphthalide in the treatment of acute cerebral infarction. Methods Totally 200 cases of acute cerebral infarction in Cadre Ward of Baoji City People Hospital were randomly divided into observation group and control group, each group had 100 cases. The patients in observation group were given edaravone combined with butylphthalide, and the patients in control group were given butylphthalide treatment. The clinical efficacy, NDS score, MoCA score, and adverse reaction of the two groups were compared. Results The total effective rate of observation group (92%) was significantly higher than that of control group (79%), and the difference was statistically significant (P<0.05). After treatment, two groups of patients with neurological deficits were decreased, cognitive function was improved, but the observation group was significantly lower than the control group, the improvement of cognitive function was better than the control group, ADL score of observation group was significantly higher than that of the control group, hs-CRP levels were significantly lower than the control group, the difference was statistically significant (P<0.05). All patients had no obvious adverse reactions during the treatment. Conclusion Edaravone combined with butylphthalide significantly on acute cerebral infarction curative effect, good safety, and is worthy of clinical promotion.
[中图分类号]
[基金项目]